EP1240102A1 - Hydroxyapatite contenant du phosphate tricalcique, a structure microporeuse - Google Patents
Hydroxyapatite contenant du phosphate tricalcique, a structure microporeuseInfo
- Publication number
- EP1240102A1 EP1240102A1 EP00967869A EP00967869A EP1240102A1 EP 1240102 A1 EP1240102 A1 EP 1240102A1 EP 00967869 A EP00967869 A EP 00967869A EP 00967869 A EP00967869 A EP 00967869A EP 1240102 A1 EP1240102 A1 EP 1240102A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- tricalcium phosphate
- bone
- phosphate
- algae
- content
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000463 material Substances 0.000 title claims abstract description 75
- 229910052588 hydroxylapatite Inorganic materials 0.000 title claims abstract description 56
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 title claims abstract description 56
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 title claims abstract description 50
- 239000001506 calcium phosphate Substances 0.000 title claims abstract description 46
- 229910000391 tricalcium phosphate Inorganic materials 0.000 title claims abstract description 43
- 235000019731 tricalcium phosphate Nutrition 0.000 title claims abstract description 43
- 229940078499 tricalcium phosphate Drugs 0.000 title claims abstract description 43
- 241000195493 Cryptophyta Species 0.000 claims abstract description 37
- 238000000034 method Methods 0.000 claims abstract description 28
- 239000000316 bone substitute Substances 0.000 claims abstract description 13
- 229910019142 PO4 Inorganic materials 0.000 claims abstract description 9
- 239000010452 phosphate Substances 0.000 claims abstract description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims abstract description 6
- 239000004480 active ingredient Substances 0.000 claims abstract description 5
- 239000007795 chemical reaction product Substances 0.000 claims abstract description 5
- 150000002894 organic compounds Chemical class 0.000 claims abstract description 5
- 239000012876 carrier material Substances 0.000 claims abstract description 4
- 230000000717 retained effect Effects 0.000 claims abstract description 3
- 239000011777 magnesium Substances 0.000 claims description 23
- 210000001519 tissue Anatomy 0.000 claims description 16
- 238000006243 chemical reaction Methods 0.000 claims description 15
- 210000000988 bone and bone Anatomy 0.000 claims description 14
- 159000000003 magnesium salts Chemical class 0.000 claims description 8
- 239000007858 starting material Substances 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- -1 polytetrafluoroethylene Polymers 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 4
- YIXJRHPUWRPCBB-UHFFFAOYSA-N magnesium nitrate Chemical compound [Mg+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O YIXJRHPUWRPCBB-UHFFFAOYSA-N 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 238000001356 surgical procedure Methods 0.000 claims description 4
- 241001474374 Blennius Species 0.000 claims description 3
- 239000013543 active substance Substances 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 3
- 235000011010 calcium phosphates Nutrition 0.000 claims description 3
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 3
- 241000218671 Ephedra Species 0.000 claims description 2
- 230000000259 anti-tumor effect Effects 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 14
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 abstract description 11
- 229910001425 magnesium ion Inorganic materials 0.000 abstract description 11
- 239000002994 raw material Substances 0.000 abstract 1
- 229910052749 magnesium Inorganic materials 0.000 description 18
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 15
- 239000012071 phase Substances 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000011575 calcium Substances 0.000 description 7
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 7
- 229910052791 calcium Inorganic materials 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 238000001027 hydrothermal synthesis Methods 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000011164 ossification Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical group [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 229910052586 apatite Inorganic materials 0.000 description 3
- 238000006065 biodegradation reaction Methods 0.000 description 3
- 239000000395 magnesium oxide Substances 0.000 description 3
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000242757 Anthozoa Species 0.000 description 2
- 235000014653 Carica parviflora Nutrition 0.000 description 2
- 229910017958 MgNH Inorganic materials 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- CVPJXKJISAFJDU-UHFFFAOYSA-A nonacalcium;magnesium;hydrogen phosphate;iron(2+);hexaphosphate Chemical compound [Mg+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Fe+2].OP([O-])([O-])=O.OP([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O CVPJXKJISAFJDU-UHFFFAOYSA-A 0.000 description 2
- 229940058401 polytetrafluoroethylene Drugs 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 229910052591 whitlockite Inorganic materials 0.000 description 2
- 229910021532 Calcite Inorganic materials 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 235000011116 calcium hydroxide Nutrition 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 229910000388 diammonium phosphate Inorganic materials 0.000 description 1
- 235000019838 diammonium phosphate Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000010335 hydrothermal treatment Methods 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 230000002879 macerating effect Effects 0.000 description 1
- 150000002680 magnesium Chemical class 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005245 sintering Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/12—Phosphorus-containing materials, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B25/00—Phosphorus; Compounds thereof
- C01B25/16—Oxyacids of phosphorus; Salts thereof
- C01B25/26—Phosphates
- C01B25/32—Phosphates of magnesium, calcium, strontium, or barium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Definitions
- Tricalcium phosphate-containing hydroxyapatite material with a microporous structure Tricalcium phosphate-containing hydroxyapatite material with a microporous structure
- the invention relates to a tricalcium phosphate-containing hydroxyapatite material, a process for its preparation and the use of the
- Hydroxyapatite material in the field of bone surgery and as a filter material is Hydroxyapatite material in the field of bone surgery and as a filter material.
- the bone implant In order to facilitate the growth in the body, the bone implant should have a structure that that of the
- Bone is as similar as possible.
- the implant material should also be suitable as a carrier for active substances, such as growth-promoting or inhibiting substances.
- a hydroxyapatite material which consists of the Calcium carbonate skeleton is obtained from lime-encrusting algae. Such a material is described in DE 37 09 897 C2. To mask the magnesium naturally present in the algae and the formation of (ß-tricalcium phosphate during the production of the
- the reaction mixture To prevent Hydroxyapatit Mate ⁇ als, there is preferably added Fluo ⁇ d to the reaction mixture.
- the granular hydroxylapatite material obtained by hydrothermal synthesis with slaked lime as a binder is vibrated into a molded body and then subjected to hydrothermal treatment again.
- the bone implant thus obtained has a high mterconnective porosity and a high specific surface. In its chemistry and crystalline structure, it is much more similar to bones than other bone replacement materials.
- hydroxyapatite material Despite the excellent properties of the hydroxyapatite material described in DE 37 09 897 C2, it is desirable to have a bone substitute material available whose absorption in the organism is further improved and which leads to an even faster new bone formation. It has been found that hydroxyapatite material has relatively good biological properties
- Tricalciumphosphac the organic degradation time of tricalcium phosphate is much shorter. It is desirable to have a biodegradation time that is approximately synchronized with the time with which the bone grows in place of the degraded bone substitute material. This leads to the requirement on the bone substitute material that the breakdown time can be set at least within certain limits during production and thus accelerated bone formation is promoted without the material being broken down too quickly and thus creating an interstice filled with connective tissue, for example.
- the object of the invention is to provide a bone substitute material which has a high interconnected pore structure, is very well tolerated by the body and has improved and controllable absorption in the organism and thus leads to accelerated new bone formation.
- the bone substitute material should also be suitable as a carrier for active ingredients such as growth-promoting or inhibiting substances.
- the problem is solved with the tricalcium phosphate-containing hydroxyapatite material with a microporous structure according to claim 1.
- the invention further relates to a method for producing this material according to claim 5 and its use in particular in bone surgery and as a filter material according to claim 19. Preferred embodiments and Procedures are set out in the subclaims.
- Tricalcium phosphate content which is significantly higher than that of a hydroxyapatite material, which was obtained in a conventional manner from calcareous algae.
- ß-tricalcium phosphate in hydroxylapatite material, which consists of lime encrusted Algae was obtained depends on the amount of magnesium ions that are present in the production of the hydroxyapatite material.
- naturally occurring algae naturally have a certain magnesium content.
- This natural content of magnesium in algae is normally around 2.5%, in exceptional cases up to around 6% by weight. This leads to a content of up to 10% by weight, in exceptional cases also up to about 20% by weight, of ⁇ -tricalcium phosphate in a hydroxyapatite material prepared from these algae according to DE 37 09 897 C2.
- the magnesium is present in the algae in an at least partially m form that is embedded in the structure, namely predominantly in the form of MgC0 3 , MgO and (Ca, Mg) COj, which apparently means that this magnesium is not only ß-Tncalciumphosphat is generated, but also other disturbing phases with magnesium content are generated.
- MgC0 3 , MgO and (Ca, Mg) COj which apparently means that this magnesium is not only ß-Tncalciumphosphat is generated, but also other disturbing phases with magnesium content are generated.
- the magnesium naturally present in the algae starting material is masked by the targeted addition of fluorine ions in order to suppress the formation of the calcium phosphate.
- the invention is based on the knowledge that a hydroxyapatite material with a T ⁇ calciumphosphat content, which is higher than the content that would automatically set when using a certain type of algae as the starting material, with regard to absorption in the organism and the requirement of New bone formation is improved compared to the conventional hydroxyapatite material without the other advantageous properties deteriorating.
- This increased tricalcium phosphate content is achieved through the targeted addition of magnesium ions during the production of the material.
- the invention thus relates to a tricalcium phosphate-containing hydroxylapatite material which can be obtained by converting an algae hard tissue freed from organic compounds into an alkaline aqueous solution
- the tricalcium phosphate content in the end product is preferably between 50 and 90% by weight.
- magnesium ions in the form of a magnesium salt to the mixture of the solid starting materials (hard algae tissue and phosphate salt).
- the addition of the magnesium ions must not exceed 15% by weight, since otherwise an excessive amount of other undesirable magnesium-containing phases, such as e.g. ß-Dittmarit (MgNH 4 P0 4 * 6H 2 0).
- the Mg 2+ contents in the mixture of the solid starting materials should be between 0.75 and 6% by weight.
- the tricalcium phosphate-containing hydroxylapatite material according to the invention combines all the advantages which are already known from the material described in DE 37 09 897 C2.
- the hydroxyapatite material according to the invention retains the microporous structure of the algae hard tissue, which was used as the starting material, and thus has a very high interconnectivity porosity. Because of the large porosity, the hydroxyapatite material according to the invention can also be used excellently as a filter material.
- the specific surface of the material is very high. The material is very well tolerated by the body and chemically similar to bone, making it an excellent bone replacement material.
- the tricalcium phosphate content and thus the resorptive properties can also be specifically adjusted via the concentration of the magnesium ions. With increasing tricalcium phosphate content, absorption in the body becomes faster. Conversely, a higher hydroxylapatite content slows down absorption.
- the hydroxyapatite material according to the invention is also exceptionally suitable as a carrier material for active substances such as growth-promoting or inhibiting substances. Specific examples are antibiotics, chemotherapy drugs, anti-tumor compounds and bone-inducing substances. Bone morphogenic proteins (BMP), for example, can be mentioned as bone-inductive substances.
- the tricalcium phosphate-containing hydroxylapatite material contains at least one active ingredient.
- This can either be in the hydroxyapatite material according to the invention or in the material produced from it Bone substitute material can be incorporated, or it is present as a coating on a bone substitute material which was produced using the hydroxyapatite material containing tricalcium phosphate according to the invention.
- the at least one active ingredient is expediently applied or mixed in to the hydroxylapatite material or the bone substitute material in a clinically active amount.
- any algae hard tissue that has previously been used for the production of hydroxlapatite materials can be used as the algae hard tissue, which is used as the starting material for the hydroxyapatite material according to the invention.
- Algae hard tissue which was obtained from calcareous seaweed, is particularly suitable.
- the species Amphiroa Ephedra, Corallinacea or Codiacea can be mentioned as examples of these seaweed.
- These algae are expediently macerated, for example pyrolyzed at 700 ° C. for about a day and then granulated.
- the hard algae tissue obtained consists predominantly of calcium carbonate (approx. 95% by weight), the remaining approximately 5% by weight are mainly calcium oxide and magnesium oxide.
- Algae hard tissue and phosphate salt are selected in a manner known per se so that the ratio of calcium to phosphorus corresponds to the ratio in the hydroxyapatite.
- the ratio of calcium to phosphorus in the hydroxyapatite is about 1.67.
- the weight ratio of hard algae to phosphate salt is Usually in the range of 1: 0.8 to 1: 1.5, preferably 1: 0.95 to 1: 1. The weight ratio fluctuates somewhat depending on the calcium content of the hard algae tissue used.
- the magnesium salt is expediently added in such an amount that the content of tricalcium phosphate in the end product is between 50 and 90% by weight.
- Magnesium nitrate is used as the preferred source of the magnesium ions. In principle, however, other water-soluble magnesium salts can also be used.
- diammonium hydrogen phosphate serves as the preferred phosphate compound.
- the method according to the invention is not restricted to this salt.
- reaction components mentioned above are reacted in alkaline at elevated temperature.
- a preferred pH range is between 8 and 11.
- the reaction is particularly expedient at a pH between 9 and 9.5.
- all water-soluble bases can be used to adjust the pH.
- Ammonia is particularly preferred.
- a suitable temperature range for carrying out the process according to the invention is between 150 and 250 ° C., in particular between 200 and 250 ° C.
- a particularly preferred temperature range is between 230 and 250 ° C. At this temperature, the reaction will usually take at least 24 hours.
- the method according to the invention is expediently carried out at elevated pressure. It has proven particularly suitable to carry out the reaction in an autoclave. Preferably, one with an inert coating provided autoclave. An autoclave lined with polytetrafluoroethylene is particularly suitable.
- the autoclave is expediently filled to a maximum of two thirds so that the saturated steam pressure can be established during the implementation.
- An algae hard material obtained by macerating algae of the species Corallma officmalis is filled in the form of a granulate with a grain size of more than 0.5 mm.
- (NH 4 ) 2 HP0 4 is used as the phosphate salt.
- the weight ratio of hard algae to the phosphate salt is 1: 0.95.
- the phosphate salt is added in the form of a water solution, the weight ratio of phosphate salt to water being about 1: 4.
- Magnesium is also added to the autoclave in the form of Mg (N0 3 ) 2 .6H 2 0. The amount is 2.5% by weight of magnesium, based on the solids content in the autoclave.
- Process steps (a), (b) and (d) correspond to example 1, but the synthesis is carried out in a temperature range from 200 ° C. to 240 ° C.
- the temperature m of this embodiment varies, the
- Synthesis first takes place for two hours at a temperature of 200 ° C. Then the temperature is raised to 240 ° C for the next two hours, then reset to 200 ° C. This cycle is again maintained for a total of 24 hours. The change in
- the change in the sintering temperature changes the thermodynamic conditions in the autoclave during the entire process, so that the crystallization processes take place, but the growth of the crystallites is slowed down and these ultimately remain small. This is a procedure for maintaining the stability of the algae skeleton.
- the tricalcium phosphate phase has a crystallite size of 100 to 150 rar and the apatite phase a crystallite size of approx. 50 nm.
- a crystallite size of 30 nm can be used for the apatite phase and 40 to 45 for the tricalcium phosphate phase nm can be reached.
- the temperature of the hydrothermal synthesis can also be varied between 200 ° C. and 240 ° C. every four hours.
- the highest concentrations of tricalcium phosphate in the product according to the present invention is approximately 90%, the remainder being mainly hydroxylapatite.
- the structure is stable and the individual cores of the granulate are hard enough.
- the maximum amount of Mg added is 5.5 to 6.0% by weight, calculated on the amount of the burned algae (calcite hard tissue).
- the addition is approx. 0.75% by weight, at a desired concentration of 60% approx. 3.0% by weight. So there is a leap in terms of the addition of Mg, which is necessary to achieve a concentration of tricalcium phosphate of well over 50%. Such a concentration can be achieved with the described, particularly suitable procedure of temperature variation.
- the excess amount of magnesium required for the reaction is thus given the function of a catalyst which the natural proportion of magnesium in the burned algae does not have in the form of MgC0 3 , MgO and (Ca, Mg) C0 3 integrated in the crystal network.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19950113A DE19950113A1 (de) | 1999-10-18 | 1999-10-18 | Tricalciumphosphat-haltiges Hydroxylapatit-Material |
| DE19950113 | 1999-10-18 | ||
| PCT/EP2000/010117 WO2001028919A1 (fr) | 1999-10-18 | 2000-10-13 | Hydroxyapatite contenant du phosphate tricalcique, a structure microporeuse |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP1240102A1 true EP1240102A1 (fr) | 2002-09-18 |
| EP1240102B1 EP1240102B1 (fr) | 2004-10-27 |
Family
ID=7926022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP00967869A Expired - Lifetime EP1240102B1 (fr) | 1999-10-18 | 2000-10-13 | Hydroxyapatite contenant du phosphate tricalcique, a structure microporeuse |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1240102B1 (fr) |
| AT (1) | ATE280736T1 (fr) |
| AU (1) | AU7787500A (fr) |
| DE (2) | DE19950113A1 (fr) |
| WO (1) | WO2001028919A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPR152100A0 (en) | 2000-11-16 | 2000-12-14 | University Of Technology, Sydney | Method for treating coral |
| DE10113108B4 (de) * | 2001-03-15 | 2007-07-26 | Dot Gmbh | Wirkstoffhaltige Calciumphosphat-Materialien |
| KR20020096521A (ko) * | 2001-06-20 | 2002-12-31 | 홍국선 | 고강도 생체활성 세라믹복합체 및 그 제조방법 |
| GB0609815D0 (en) * | 2006-05-18 | 2006-06-28 | Univ Belfast | Process for preparing hydroxylapatite |
| DK3777904T3 (da) * | 2019-08-16 | 2022-07-04 | Univ Heidelberg | Osteotrop knogleerstatning |
| CN112358317A (zh) * | 2020-11-20 | 2021-02-12 | 佳木斯大学 | 一种医用骨再生修复纳米生物陶瓷材料及其制备方法与应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3929971A (en) * | 1973-03-30 | 1975-12-30 | Research Corp | Porous biomaterials and method of making same |
| JPS59171545A (ja) * | 1983-03-18 | 1984-09-28 | 株式会社 吉田製作所 | リン酸カルシウム複合剤 |
| DE3542744C1 (de) * | 1985-12-03 | 1987-05-27 | Ewers Rolf | Poroeses Hydroxylapatit-Material |
| DE3709897A1 (de) * | 1987-03-26 | 1988-10-06 | Ewers Rolf | Verfahren zur herstellung eines hydroxylapatitmaterials |
| GB9215356D0 (en) * | 1992-07-20 | 1992-09-02 | Univ Reading The | Bone materials |
| US5783217A (en) * | 1995-11-07 | 1998-07-21 | Etex Corporation | Low temperature calcium phosphate apatite and a method of its manufacture |
| BG101544A (en) * | 1997-05-30 | 1998-11-30 | Медицински Университет-Ректорат | Method for the preparation of biologically active coatings over titanium osteal implants |
-
1999
- 1999-10-18 DE DE19950113A patent/DE19950113A1/de not_active Withdrawn
-
2000
- 2000-10-13 EP EP00967869A patent/EP1240102B1/fr not_active Expired - Lifetime
- 2000-10-13 DE DE50008445T patent/DE50008445D1/de not_active Expired - Lifetime
- 2000-10-13 WO PCT/EP2000/010117 patent/WO2001028919A1/fr not_active Ceased
- 2000-10-13 AT AT00967869T patent/ATE280736T1/de not_active IP Right Cessation
- 2000-10-13 AU AU77875/00A patent/AU7787500A/en not_active Abandoned
Non-Patent Citations (1)
| Title |
|---|
| See references of WO0128919A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| DE50008445D1 (de) | 2004-12-02 |
| ATE280736T1 (de) | 2004-11-15 |
| EP1240102B1 (fr) | 2004-10-27 |
| DE19950113A1 (de) | 2001-05-03 |
| AU7787500A (en) | 2001-04-30 |
| WO2001028919A1 (fr) | 2001-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0984901B1 (fr) | Gel d'hydroxylapatite | |
| DE69702610T2 (de) | Verfahren zur herstellung von hydroxylapatit-beschichtungen | |
| DE60318613T2 (de) | Apatit/collagen-vernetztes poröses material mit selbstorganisiertem apatit/collagen-verbundstoff und herstellungsverfahren dafür | |
| EP0003979B1 (fr) | Dépôt pharmaceutique implantable et méthode pour sa fabrication | |
| DE69909850T2 (de) | Mit einem magnesiumsalz stabilisierter hydraulischer brushitzement | |
| DE2724972C2 (fr) | ||
| DE3831260C2 (fr) | ||
| EP1121161B1 (fr) | Composition pour implantation dans le corps d'un homme ou d'un animal | |
| EP1153621A1 (fr) | Biociments basés sur le mélange TCP-PHA présentant une résistance améliorée à la compression | |
| DE69804506T2 (de) | Verfahren zur herstellung von mit karbonat und magnesium substituiertem hydroxyapatit | |
| DE60201528T2 (de) | Herstellungsprozess biofunktioneller hydroxylapatitbeschichtungen und mikrosphären für in-situ wirkstoffverkapselung | |
| DE68928816T2 (de) | Kalziumphosphatmineralzusammensetzungen sowie Verfahren zu deren Herstellung | |
| DE68912302T2 (de) | Härtendes material für medizinischen und dentalen gebrauch. | |
| DE69228793T2 (de) | Verfahren zur herstellung eines mit hydroxylapatit überzogenen implantats | |
| DE69809158T2 (de) | Calciumphosphatzement und Calciumphosphatzementzusammensetzung | |
| EP1511521B1 (fr) | Preparations de ciment d'apatite de strontium et leurs utilisations | |
| DE3038047A1 (de) | Fuellmaterial | |
| CH632158A5 (de) | Knochenersatz-, knochenverbund- oder prothesenverankerungswerkstoff. | |
| DE4124898A1 (de) | Mit apatit ueberzogene tetracalciumphosphat-teilchen | |
| CH664086A5 (de) | Glasfasermaterial. | |
| EP1240102B1 (fr) | Hydroxyapatite contenant du phosphate tricalcique, a structure microporeuse | |
| DE3872862T2 (de) | Zusammensetzung zur herstellung eines haertbaren calciumphosphatartigen materials und verfahren zur herstellung eines derartigen materials. | |
| DE69005074T2 (de) | Biomaterial zur Füllung von Knochen oder Zähnen und Verfahren zu seiner Herstellung. | |
| EP4493529A1 (fr) | Engrais granulaire appauvri en métaux lourds et enrichi en phosphate, procédé de production, dispositif et utilisation | |
| EP0237043B1 (fr) | Matériau biocompatible en forme de feuille contenant du phosphate de calcium et son procédé de préparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20020416 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
| AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
| 17Q | First examination report despatched |
Effective date: 20021029 |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT CH DE FR GB LI |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20041027 |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Free format text: NOT ENGLISH |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D Free format text: GERMAN |
|
| REF | Corresponds to: |
Ref document number: 50008445 Country of ref document: DE Date of ref document: 20041202 Kind code of ref document: P |
|
| GBT | Gb: translation of ep patent filed (gb section 77(6)(a)/1977) |
Effective date: 20050228 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: RN |
|
| LTIE | Lt: invalidation of european patent or patent extension |
Effective date: 20041027 |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FD4D |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: FC |
|
| EN | Fr: translation not filed | ||
| ET | Fr: translation filed | ||
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| 26N | No opposition filed |
Effective date: 20050728 |
|
| EN | Fr: translation not filed | ||
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: EERR Free format text: CORRECTION DE BOPI 05/51 - BREVETS EUROPEENS DONT LA TRADUCTION N A PAS ETE REMISE A L INPI. IL Y A LIEU DE SUPPRIMER : LA MENTION DE LA NON REMISE. LA REMISE DE LA TRADUCTION EST A CONSIDERER COMME NULLE ET NON AVENUE. |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: PATENTANWAELTE KLEIN & KLEIN Ref country code: CH Ref legal event code: PUE Owner name: ALGIPAT PROJECT HOLDING GMBH Free format text: JORDANOVA-SPASSOVA, MARGARITA#BL. 3, EING. A, APP. 10, BOUL. "PETKO TODOROV"#1404 SOFIA (BG) -TRANSFER TO- ALGIPAT PROJECT HOLDING GMBH#DOMINIKANERBASTEI 19#1010 WIEN (AT) |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: TP |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20091014 Year of fee payment: 10 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20091123 Year of fee payment: 10 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20110630 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20101013 |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E Free format text: REGISTERED BETWEEN 20110908 AND 20110914 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: ISLER & PEDRAZZINI AG Ref country code: CH Ref legal event code: PUE Owner name: LOGON PATENTVERWERTUNGS-VERWALTUNGS GMBH Free format text: ALGIPAT PROJECT HOLDING GMBH#DOMINIKANERBASTEI 19#1010 WIEN (AT) -TRANSFER TO- LOGON PATENTVERWERTUNGS-VERWALTUNGS GMBH#MUDERBOLZ 5 1/2#87527 OFTERSCHWANG (DE) |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R081 Ref document number: 50008445 Country of ref document: DE Owner name: LOGON PATENTVERWERTUNGS-VERWALTUNGS GMBH, DE Free format text: FORMER OWNER: ALGIPAT GMBH, WIEN, AT Effective date: 20120209 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20101031 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20151026 Year of fee payment: 16 Ref country code: CH Payment date: 20151026 Year of fee payment: 16 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20161102 Year of fee payment: 17 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
| GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20161013 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161013 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161031 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161031 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 50008445 Country of ref document: DE |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180501 |